Botanix Pharmaceuticals (BXPHF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

I'm Vincent Polito, the Executive Chairman. I'm joining you from our U.S. headquarters in Phoenix, Arizona. Joined with me on this presentation this morning, live from Australia, are both our Chief Executive Officer, Dr. Howie McGibbon, and our Chief Financial Officer, Chris Lesovitz. We've got almost 350 people participants that were preregistered for this conference today. So following the presentation, we're going to take some Q&A. Obviously, with that many people, we'll take as many as we can in the time that is permitted here for it. With that, David, would you advance to the next slide, please? I'd like to point out in our investor update is an important notice and disclaimers that this presentation may contain certain forward-looking statements. I would encourage you to view our 4C quarterly cash report and this Q1 fiscal year 2026 investor update. But more importantly, I'll read our important notices and disclaimers. And with that, I'm going to turn the presentation over to Dr. Howie McGibbon. Howie? Yeah, thank you, Vince, and thank you all for joining the Botanics Q1 quarterly update. Chris and I are out here in Noosa for the Canaccord Wilson's Drug and Device Conference, followed by a roadshow next week in Sydney and Milliburn. We're going to do this a few times a year, typically following one of our filings. Today, we'll provide a corporate overview for those of you that are new to the Botanics story. We're going to review our strong Q1 commercial performance, discuss our key financial highlights, which leave us in a very strong financial position to support profitability. And then we're going to preview our Q2 activity. Next slide, David. Again, for those that are new, Botanics is a fast-growing dermatology company. with the recent successful launch of o...